6TXF
Crystal structure of tetrameric human D137N-SAMHD1 (residues 109-626) with XTP, dAMPNPP and Mn
6TXF の概要
エントリーDOI | 10.2210/pdb6txf/pdb |
関連するPDBエントリー | 6TX0 6TXA 6TXC 6TXE |
分子名称 | Deoxynucleoside triphosphate triphosphohydrolase SAMHD1, FE (III) ION, MANGANESE (II) ION, ... (6 entities in total) |
機能のキーワード | triphosphohydrolase, metallo-enzyme, binuclear, hd, hydrolase |
由来する生物種 | Homo sapiens (Human) |
タンパク質・核酸の鎖数 | 2 |
化学式量合計 | 123866.07 |
構造登録者 | Morris, E.R.,Kunzelmann, S.,Caswell, S.J.,Arnold, L.H.,Purkiss, A.G.,Kelly, G.,Taylor, I.A. (登録日: 2020-01-14, 公開日: 2020-06-24, 最終更新日: 2024-01-24) |
主引用文献 | Morris, E.R.,Caswell, S.J.,Kunzelmann, S.,Arnold, L.H.,Purkiss, A.G.,Kelly, G.,Taylor, I.A. Crystal structures of SAMHD1 inhibitor complexes reveal the mechanism of water-mediated dNTP hydrolysis. Nat Commun, 11:3165-3165, 2020 Cited by PubMed Abstract: SAMHD1 regulates cellular 2'-deoxynucleoside-5'-triphosphate (dNTP) homeostasis by catalysing the hydrolysis of dNTPs into 2'-deoxynucleosides and triphosphate. In CD4 myeloid lineage and resting T-cells, SAMHD1 blocks HIV-1 and other viral infections by depletion of the dNTP pool to a level that cannot support replication. SAMHD1 mutations are associated with the autoimmune disease Aicardi-Goutières syndrome and hypermutated cancers. Furthermore, SAMHD1 sensitises cancer cells to nucleoside-analogue anti-cancer therapies and is linked with DNA repair and suppression of the interferon response to cytosolic nucleic acids. Nevertheless, despite its requirement in these processes, the fundamental mechanism of SAMHD1-catalysed dNTP hydrolysis remained unknown. Here, we present structural and enzymological data showing that SAMHD1 utilises an active site, bi-metallic iron-magnesium centre that positions a hydroxide nucleophile in-line with the P-O bond to catalyse phosphoester bond hydrolysis. This precise molecular mechanism for SAMHD1 catalysis, reveals how SAMHD1 down-regulates cellular dNTP and modulates the efficacy of nucleoside-based anti-cancer and anti-viral therapies. PubMed: 32576829DOI: 10.1038/s41467-020-16983-2 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (2.25 Å) |
構造検証レポート
検証レポート(詳細版)をダウンロード